Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial

Fisher, Charles J.

doi:10.1001/jama.1994.03510470040032

Cited by 794Sepsis Diagnosis and TreatmentInflammation biomarkers and pathwaysAntibiotics Pharmacokinetics and Efficacy

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial

Fisher, Charles J.·1994·JAMA

DOI 10.1001/jama.1994.03510470040032

Open this paper in CoChat — free account

Abstract

Objective. —To further define the safety and efficacy of recombinant human interleukin 1 receptor antagonist (rhIL-1ra) in the treatment of sepsis syndrome. Study Design. —Randomized, double-blind, placebo-controlled, multicenter, multinational clinical trial. Population. —A total of 893 patients with sepsis syndrome received an intravenous loading dose of rhIL-1ra, 100 mg, or placebo followed by a continuous 72-hour intravenous infusion of rhIL-1ra (1.0 or 2.0 mg/kg per hour) or placebo. Outcome Measure. —Twenty-eight—day all-cause mortality. Results. —There was not a significant increase in survival time for rhIL-1ra treatment compared with placebo among all patients who received the study medication (n=893; generalized Wilcoxon statistic,P=.22) or among patients with shock at study entry (n=713; generalized Wilcoxon statistic,P=.23), the two primary efficacy analyses specified a priori for this trial. Results from secondary analyses suggest an increase in survival time with rhIL-1ra treatment among patients with dysfunction of one or more organs (n=563; linear dose-response,P=.009). Retrospective analysis demonstrated an increase in survival time with rhIL-1ra treatment among patients with a predicted risk of mortality of 24% or greater (n=580; linear dose-response,P=.005) as well as among patients with both dysfunction of one or more organs and a predicted risk of mortality of 24% or greater (n=411; linear dose-response,P=.002). Conclusions. —There was not a statistically significant increase in survivial time for rhIL-1ra treatment compared with placebo among all patients who received the study medication or among patients with shock at study entry. Secondary and retrospective analyses of efficacy suggest that treatment with rhIL-1ra results in a dose-related increase in survival time among patients with sepsis who have organ dysfunction and/or a predicted risk of mortality of 24% or greater. (JAMA. 1994;271:1836-1843)

Integrity signals

Registry

Crossref · 10.1001/jama.1994.03510470040032

Cites

0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Administration of monoclonal antibodies directed at specific cytokines and use of apheresis or medical devices to remove cytokines from circulation have had generally disappointing results in clinical trials for sepsis-associated cytokine storm.
“The administration of monoclonal antibodies directed at specific cytokines and the use of apheresis or medical devices to remove cytokines from circulation have had generally disappointing results in clinical trials.62”
From Cytokine storm (2020) · cites this paper as [62]

The publisher hasn’t deposited this paper’s reference list.

Sorted by citations

Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: Results of a multicenter, prospective study
Vincent, J.-L., de Mendonca, A., Cantraine, F., Moreno, R., Takala, J., Suter, P. M., Sprung, C. L., Colardyn, F., & Blecher, S. (1998) · Critical Care Medicine · doi:10.1097/00003246-199811000-00016 · Cited by 3,463
Cytokine storm
Fajgenbaum, D. C., & June, C. H. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2026131 · Cited by 3,196
Multiple Organ Dysfunction Score
Marshall, J. C., Cook, D. J., Christou, N. V., Bernard, G. R., Sprung, C. L., & Sibbald, W. J. (1995) · Critical Care Medicine · doi:10.1097/00003246-199510000-00007 · Cited by 2,539
Overview of the IL ‐1 family in innate inflammation and acquired immunity
Dinarello, C. A. (2018) · Immunological Reviews · doi:10.1111/imr.12621 · Cited by 1,866
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,810
Monocyte deactivation in septic patients: Restoration by IFN-γ treatment
Döcke, W.-D., Randow, F., Syrbe, U., Krausch, D., Asadullah, K., Reinke, P., Volk, H.-D., & Kox, W. (1997) · Nature Medicine · doi:10.1038/nm0697-678 · Cited by 1,190
Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis
Wang, H., Liao, H., Ochani, M., Justiniani, M., Lin, X., Yang, L., Al-Abed, Y., Wang, H., Metz, C., Miller, E. J., et al. (2004) · Nature Medicine · doi:10.1038/nm1124 · Cited by 1,170
INTERLEUKIN-1 RECEPTOR ANTAGONIST: Role in Biology
Arend, W. P., Malyak, M., Guthridge, C. J., & Gabay, C. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.27 · Cited by 1,071
Sepsis: A New Hypothesis for Pathogenesis of the Disease Process
Bone, R. C., Grodzin, C. J., & BALK, R. A. (1997) · CHEST Journal · doi:10.1378/chest.112.1.235 · Cited by 1,019
Sir Isaac Newton, sepsis, SIRS, and CARS
Bone, R. C. (1996) · Critical Care Medicine · doi:10.1097/00003246-199607000-00010 · Cited by 995
Sepsis: a roadmap for future research
Cohen, J., Vincent, J., Adhikari, N. K. J., Machado, F. R., Angus, D. C., Calandra, T., Jaton, K., Giulieri, S. G., Delaloye, J., Opal, S. M., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)70112-x · Cited by 1,027
Confirmatory interleukin-1 receptor antagonist trial in severe sepsis
Opal, S. M., Fisher, C. J., Dhainaut, J.-F., Vincent, J., Brase, R., Lowry, S. F., SADOFF, J. C., Slotman, G. J., Levy, H. A., BALK, R. A., et al. (1997) · Critical Care Medicine · doi:10.1097/00003246-199707000-00010 · Cited by 882
Self-citation
Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial*
Shakoory, B., Carcillo, J. A., Chatham, W. W., Amdur, R. L., Zhao, H., Dinarello, C. A., Cron, R. Q., & Opal, S. M. (2016) · Critical Care Medicine · doi:10.1097/ccm.0000000000001402 · Cited by 867
Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure
Fowler, A. A., Truwit, J. D., Hite, R. D., Morris, P. E., DeWilde, C., Priday, A., Fisher, B., Thacker, L. R., Natarajan, R., Brophy, D. F., et al. (2019) · JAMA · doi:10.1001/jama.2019.11825 · Cited by 836
Novel strategies for the treatment of sepsis
Riedemann, N. C., Guo, R., & Ward, P. A. (2003) · Nature Medicine · doi:10.1038/nm0503-517 · Cited by 774
Interleukin-1, Interleukin-1 Receptors and Interleukin-1 Receptor Antagonist
Dinarello, C. A. (1998) · International Reviews of Immunology · doi:10.3109/08830189809043005 · Cited by 761
Transient expression of IL-1β induces acute lung injury and chronic repair leading to pulmonary fibrosis
Kolb, M. R. J., Margetts, P. J., Anthony, D. C., Pitossi, F. J., & Gauldie, J. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12568 · Cited by 754
Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis
Fergusson, D., Aaron, S. D., Guyatt, G., & Hébert, P. (2002) · BMJ · doi:10.1136/bmj.325.7365.652 · Cited by 708
Anti-inflammatory therapies to treat sepsis and septic shock
Zéni, F., Freeman, B. D., & Natanson, C. (1997) · Critical Care Medicine · doi:10.1097/00003246-199707000-00001 · Cited by 648
Has the mortality of septic shock changed with time?
Friedman, G., Silva, E., & Vincent, J. (1998) · Critical Care Medicine · doi:10.1097/00003246-199812000-00045 · Cited by 597
Sepsis and the Heart
Merx, M. W., & Weber, C. (2007) · Circulation · doi:10.1161/circulationaha.106.678359 · Cited by 603
Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation
Ulloa, L., Ochani, M., Yang, H., Tanovic, M., Halperin, D. M., Yang, R., Czura, C. J., Fink, M. P., & Tracey, K. J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192222999 · Cited by 585
Animal models of sepsis and sepsis-induced kidney injury
Doi, K., Leelahavanichkul, A., Yuen, P. S. T., & Star, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39421 · Cited by 585
American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 1
Henderson, L. A., Canna, S., Friedman, K. G., Gorelik, M., Lapidus, S., Bassiri, H., Behrens, E. M., Ferris, A. M., Kernan, K. F., Schulert, G. S., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41454 · Cited by 540
The relationship between inflammatory and serosal connective tissue changes in ileal Crohn's disease: evidence for a possible causative link
Borley, N. R., Mortensen, N. J. M., Jewell, D. P., & Warren, B. F. (2000) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(200002)190:2 · Cited by 158
Proinflammatory and Anti-inflammatory Cytokines as Mediators in the Pathogenesis of Septic Shock
Dinarello, C. A. (1997) · CHEST Journal · doi:10.1378/chest.112.6_supplement.321s · Cited by 505
Pathophysiology of Sepsis
Remick, D. G. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.060872 · Cited by 524
The American–European Consensus Conference on ARDS, Part 2: Ventilatory, Pharmacologic, Supportive Therapy, Study Design Strategies, and Issues Related to Recovery and Remodeling
Artigas, A., Bernard, G. R., Carlet, J. M., Dreyfuss, D., Gattinoni, L., Hudson, L. D., Lamy, M., Marini, J. J., Matthay, M. A., Pinsky, M. R., et al. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.4.ats2-98 · Cited by 471
The vagus nerve and the nicotinic anti-inflammatory pathway
Ulloa, L. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1797 · Cited by 470
Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter series
Nigrovic, P. A., Mannion, M. L., Prince, F. H. M., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.30128 · Cited by 464
Systemic inflammatory response syndrome
Davies, M. G., & Hagen, P.-O. (1997) · British journal of surgery · doi:10.1002/bjs.1800840707 · Cited by 490
Sepsis: Multiple Abnormalities, Heterogeneous Responses, and Evolving Understanding
Iskander, K. N., Osuchowski, M. F., Stearns-Kurosawa, D. J., Kurosawa, S., Stepien, D. M., Valentine, C., & Remick, D. G. (2013) · Physiological Reviews · doi:10.1152/physrev.00037.2012 · Cited by 469
Severe sepsis in cirrhosis†
Gustot, T., Durand, F., Lebrec, D., Vincent, J., & Moreau, R. (2009) · Hepatology · doi:10.1002/hep.23264 · Cited by 445
The dark side of C5a in sepsis
Ward, P. A. (2004) · Nature reviews. Immunology · doi:10.1038/nri1269 · Cited by 420
The Significance of Vasoactive Intestinal Peptide in Immunomodulation
Delgado, M., Pozo, D., & Ganea, D. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.7 · Cited by 415
“…antagonists of platelet activating factor (Dhainaut et al., 1994), antagonists of bradykinin (Fein et al., 1997), IL-1 receptor antagonists (Fisher et al., 1994), and monoclonal anti-TNF antibodies (Abraham et al., 1995) or soluble dimeric TNF receptor fusion proteins (Fisher et al., 1996).”
Background
American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 2
Henderson, L. A., Canna, S., Friedman, K. G., Gorelik, M., Lapidus, S., Bassiri, H., Behrens, E. M., Ferris, A. M., Kernan, K. F., Schulert, G. S., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41616 · Cited by 431
The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome
Wang, H., & Ma, S. (2008) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2007.10.031 · Cited by 406
“As numerous cytokines and redundant pathways are involved in the local inflammatory response, cytokinetargeted therapy on single pathways is insufficient to improve outcomes [38-40].”
Background
The disconnect between animal models of sepsis and human sepsis
Rittirsch, D., Hoesel, L. M., & Ward, P. A. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.0806542 · Cited by 421
“related mortality in large clinical trials [26].”
Prognostic and predictive enrichment in sepsis
Stanski, N. L., & Wong, H. R. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0199-3 · Cited by 399
Animal models of sepsis
Fink, M. P. (2014) · Virulence · doi:10.4161/viru.26083 · Cited by 391
The NLRP3 inflammasome in health and disease: the good, the bad and the ugly
Menu, P., & Vince, J. E. (2011) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2011.04440.x · Cited by 397
Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment
Ravelli, A., Grom, A. A., Behrens, E. M., & Cron, R. Q. (2012) · Genes and Immunity · doi:10.1038/gene.2012.3 · Cited by 381
Uncoupling of biological oscillators
Godin, P. J., & Buchman, T. G. (1996) · Critical Care Medicine · doi:10.1097/00003246-199607000-00008 · Cited by 378
The IL-1 family of cytokines and receptors in rheumatic diseases
Dinarello, C. A. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0277-8 · Cited by 384
Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock
Reinhart, K., Wiegand-Löhnert, C., Grimminger, F., Kaul, M., Withington, S., Treacher, D., Eckart, J., Willatts, S. M., Bouza, C., Krausch, D., et al. (1996) · Critical Care Medicine · doi:10.1097/00003246-199605000-00003 · Cited by 358
Monocyte deactivation-rationale for a new therapeutic strategy in sepsis
Volk, H., Reinke, P., Krausch, D., Zuckermann, H., Asadullah, K., Müller, J. M., Döcke, W. ‐., & Kox, W. J. (1996) · Intensive Care Medicine · doi:10.1007/bf01743727 · Cited by 361
Severe Sepsis and Septic Shock: Review of the Literature and Emergency Department Management Guidelines
Nguyen, H. B., Rivers, E. P., Abrahamian, F. M., Moran, G. J., Abraham, E. H., Trzeciak, S. W., Huang, D. T., Osborn, T. M., Stevens, D. L., & Talan, D. A. (2006) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2006.02.015 · Cited by 354
A second large controlled clinical study of E5, a monoclonal antibody to endotoxin
Bone, R. C., BALK, R. A., Fein, A. M., Perl, T. M., Wenzel, R. P., Reines, H. D., Quenzer, R. W., Iberti, T. J., MacIntyre, N. R., & Schein, R. M. H. (1995) · Critical Care Medicine · doi:10.1097/00003246-199506000-00003 · Cited by 347
Signaling pathways and intervention therapies in sepsis
Zhang, Y., & Ning, B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00816-9 · Cited by 369
The Systemic Inflammatory Response to Cardiopulmonary Bypass
Hall, R. I., Stafford‐Smith, M., & Rocker, G. M. (1997) · Anesthesia & Analgesia · doi:10.1097/00000539-199710000-00011 · Cited by 407
Risk and the Efficacy of Antiinflammatory Agents: Retrospective and Confirmatory Studies of Sepsis
Eichacker, P. Q., Parent, C., Kalil, A. C., Esposito, C., Cui, X., Banks, S. M., Gerstenberger, E. P., Fitz, Y., Danner, R. L., & Natanson, C. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200204-302oc · Cited by 340
Antithrombin III in patients with severe sepsis
Eisele, B., Heinrichs, H., Delvos, U., Lamy, M., THIJS, L. G., Keinecke, H.-O., Schuster, H.-P., Matthias, F. R., & Fourrier, F. (1998) · Intensive Care Medicine · doi:10.1007/s001340050642 · Cited by 334
Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis
Nylén, E., Whang, K. T., Snider, R. H., et al. (1998) · Critical Care Medicine · doi:10.1097/00003246-199806000-00015 · Cited by 327
The changing immune system in sepsis
Boomer, J. S., Green, J. M., & Hotchkiss, R. S. (2013) · Virulence · doi:10.4161/viru.26516 · Cited by 340
Role of Oxidative Stress and Mitochondrial Dysfunction in Sepsis and Potential Therapies
Mantzarlis, K. D., Tsolaki, V., & Zakynthinos, E. G. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/5985209 · Cited by 325
Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock
Alejandria, M. M., Lansang, M. A., Dans, L. F., & Mantaring, J. B. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001090 · Cited by 313
Therapeutic Neutralization of the NLRP1 Inflammasome Reduces the Innate Immune Response and Improves Histopathology after Traumatic Brain Injury
de Rivero Vaccari, J. P., Lotocki, G., Alonso, O. F., Bramlett, H. M., Dietrich, W. D., & Keane, R. W. (2009) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.46 · Cited by 312
“…introduced in clinical treatments of autoinflammatory diseases, such as rheumatoid arthritis or gout (Braddock and Quinn, 2004; Dinarello, 2005a; Fisher et al, 1994; Liao et al, 1984; So et al, 2007), and recent results of a phase II study of IL-1Ra treatment in stroke patients are encouraging…”
Current trends in inflammatory and immunomodulatory mediators in sepsis
Aziz, M., Jacob, A., Yang, W.-L., Matsuda, A., & Wang, P. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.0912437 · Cited by 309
“A controversial result between LPS model and clinical trial has been noted in anti-IL-1R antibody treatment, where the murine model shows better therapeutic efficacy than patients [153, 154].”
Background
Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era
Behrens, E. M., & Koretzky, G. A. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40071 · Cited by 307
Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock
Alejandria, M. M., Lansang, M. A., Dans, L. F., & Mantaring, J. B. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001090.pub2 · Cited by 605
Targeting Interleukin-1 in Heart Disease
Tassell, B. W. V., Toldo, S. A., Mezzaroma, E., & Abbate, A. (2013) · Circulation · doi:10.1161/circulationaha.113.003199 · Cited by 319
American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 3
Henderson, L. A., Canna, S., Friedman, K. G., Gorelik, M., Lapidus, S., Bassiri, H., Behrens, E. M., Kernan, K. F., Schulert, G. S., Seo, P., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42062 · Cited by 311
Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome
Mehta, P., Cron, R. Q., Hartwell, J., Manson, J. J., & Tattersall, R. S. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30096-5 · Cited by 291
A prospective, randomized, double-blind, controlled clinical trial of enteral immunonutrition in the critically ill
Atkinson, S., Sieffert, E., & Bihari, D. J. (1998) · Critical Care Medicine · doi:10.1097/00003246-199807000-00013 · Cited by 284
Clinical Practice Guidelines for Hospital‐Acquired Pneumonia and Ventilator‐Associated Pneumonia in Adults
Rotstein, C., Evans, G. A., Born, A., Grossman, R. F., Light, R. B., Magder, S. A., McTaggart, B., Weiss, K., & Zhanel, G. G. (2007) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2008/593289 · Cited by 282
Role of Cytokines in Sepsis
Hack, C. E., Aarden, L. A., & THUS, L. G. (1997) · Advances in immunology · doi:10.1016/s0065-2776(08)60597-0 · Cited by 286
Interleukin-1 function and role in rheumatic disease
Schett, G. A., Dayer, J., & Manger, B. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.166 · Cited by 292
Such stuff as dreams are made on: mediator-directed therapy in sepsis
Marshall, J. C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1084 · Cited by 263
Clinical Gram-positive sepsis
Opal, S. M., & Cohen, J. (1999) · Critical Care Medicine · doi:10.1097/00003246-199908000-00039 · Cited by 258
The coagulopathy of acute sepsis
Simmons, J., & Pittet, J. (2015) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000163 · Cited by 262
Immune dysregulation in sepsis: experiences, lessons and perspectives
Cao, M., Wang, G., & Xie, J. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01766-7 · Cited by 284
Sepsis and serum cytokine concentrations
Damas, P., Canivet, J.-L., Groote, D. D., Vrindts, Y., Albert, A., Franchimont, P., & Lamy, M. (1997) · Critical Care Medicine · doi:10.1097/00003246-199703000-00006 · Cited by 252
Gasdermin D inhibition prevents multiple organ dysfunction during sepsis by blocking NET formation
Silva, C. M. S., Wanderley, C. W. S., Veras, F. P., Sônego, F., Nascimento, D. C., Gonçalves, A. V., Martins, T. V., Colón, D. F., Borges, V. F., Brauer, V. S., et al. (2021) · Blood · doi:10.1182/blood.2021011525 · Cited by 270
An overview of mortality risk prediction in sepsis
Barriere, S. L., & Lowry, S. F. (1995) · Critical Care Medicine · doi:10.1097/00003246-199502000-00026 · Cited by 245
Strategies to improve drug development for sepsis
Fink, M. P., & Warren, H. S. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4368 · Cited by 246
CECAL LIGATION AND PUNCTURE VERSUS COLON ASCENDENS STENT PERITONITIS: TWO DISTINCT ANIMAL MODELS FOR POLYMICROBIAL SEPSIS
Maier, S., Traeger, T., Entleutner, M., et al. (2004) · Shock · doi:10.1097/01.shk.0000126906.52367.dd · Cited by 240
Surgical trauma: hyperinflammation versus immunosuppression?
Menger, M. D., & Vollmar, B. (2004) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-004-0472-0 · Cited by 240
IL-1β suppression of VE-cadherin transcription underlies sepsis-induced inflammatory lung injury
Xiong, S., Hong, Z., Huang, L. S., Tsukasaki, Y., Nepal, S., Di, A., Zhong, M., Wu, W., Ye, Z., Gao, X., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci136908 · Cited by 241
MYOCARDIAL DYSFUNCTION IN SEPTIC SHOCK
Kumar, A., Haery, C., & Parrillo, J. E. (2000) · Critical Care Clinics · doi:10.1016/s0749-0704(05)70110-x · Cited by 235
Predicting the Duration of Mechanical Ventilation
Seneff, M. G., Zimmerman, J. E., Knaus, W. A., Wagner, D. P., & Draper, E. A. (1996) · CHEST Journal · doi:10.1378/chest.110.2.469 · Cited by 234
Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine
Cajander, S., Kox, M., Scicluna, B. P., Weigand, M. A., Mora, R. A., Flohé, S. B., Martín‐Loeches, I., Lachmann, G., Girardis, M., García‐Salido, A., et al. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00330-2 · Cited by 248
Diffusive vs. convective therapy
Kellum, J. A., Johnson, J. P., Kramer, D. J., et al. (1998) · Critical Care Medicine · doi:10.1097/00003246-199812000-00027 · Cited by 226
Continuous plasmafiltration in sepsis syndrome
Reeves, J. H., Butt, W. W., Shann, F. A., Layton, J. E., Stewart, A. G., Waring, P. M., & Presneill, J. (1999) · Critical Care Medicine · doi:10.1097/00003246-199910000-00003 · Cited by 216
Review: Is There a Window of Opportunity for Treatment of Systemic Juvenile Idiopathic Arthritis?
Nigrovic, P. A. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38615 · Cited by 220
“While the risk of infection associated with anakinra use among children with systemic JIA is not well defined, it is reassuring that a large, placebo-controlled trial of several hundred adults with overt sepsis treated with anakinra at the extraordinary dose of 100 mg then 1–2 mg/kg/hour intravenously for 3 days showe…”
Background
In silico experiments of existing and hypothetical cytokine-directed clinical trials using agent-based modeling*
An, G. C. (2004) · Critical Care Medicine · doi:10.1097/01.ccm.0000139707.13729.7d · Cited by 217
Lymphocyte function in wound healing and following injury
Schäffer, M. R., & Barbul, A. (1998) · British journal of surgery · doi:10.1046/j.1365-2168.1998.00734.x · Cited by 215
Pathophysiology of Sepsis-Related Cardiac Dysfunction: Driven by Inflammation, Energy Mismanagement, or Both?
Drosatos, K., Lymperopoulos, A., Kennel, P. J., Pollak, N. M., Schulze, P. C., & Goldberg, I. J. (2014) · Current Heart Failure Reports · doi:10.1007/s11897-014-0247-z · Cited by 219
Essential Role of Gamma Interferon in Survival of Colon Ascendens Stent Peritonitis, a Novel Murine Model of Abdominal Sepsis
Zantl, N., Uebe, A., Neumann, B., Wagner, H., Siewert, J., Holzmann, B., Heidecke, C.-D., & Pfeffer, K. (1998) · Infection and Immunity · doi:10.1128/iai.66.5.2300-2309.1998 · Cited by 206
Proteolytic Cleavage of High Mobility Group Box 1 Protein by Thrombin-Thrombomodulin Complexes
Ito, T., Kawahara, K., Okamoto, K., Yamada, S., Yasuda, M., Imaizumi, H., Nawa, Y., Meng, X., Shrestha, B., Hashiguchi, T., et al. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.150631 · Cited by 205
EVALUATION OF ENDOTOXIN MODELS FOR THE STUDY OF SEPSIS
Remick, D. G., & Ward, P. A. (2005) · Shock · doi:10.1097/01.shk.0000191384.34066.85 · Cited by 205
An open-label dose escalation study of the nitric oxide synthase inhibitor, NG-methyl-L-arginine hydrochloride (546C88), in patients with septic shock
Grover, R., Zaccardelli, D., Colice, G., Guntupalli, K. K., Watson, D. I., & Vincent, J. (1999) · Critical Care Medicine · doi:10.1097/00003246-199905000-00025 · Cited by 197
The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1βPreprint
Shchors, K., Shchors, E., Rostker, F., Lawlor, E. R., Swigart, L. B., & Evan, G. I. (2006) · Genes & Development · doi:10.1101/gad.1455706 · Cited by 200
“…tumor suppressor pathways have been circumvented, both efficiently and rapidly inducing tumors with all the “hallmarks” of advanced cancers, including angiogenesis, dysplasia, suppressed apoptosis, invasion, and metastasis (Fisher et al. 1994; Pelengaris et al. 1999, 2002; Tang et al. 2005).”
Cytokines and the immunomodulatory function of the vagus nerve
Johnston, G. R., & Webster, N. R. (2009) · British Journal of Anaesthesia · doi:10.1093/bja/aep037 · Cited by 205
Neutrophil pyroptosis: new perspectives on sepsis
Liu, L., & Sun, B. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03060-1 · Cited by 200
Untitled work
(1997) · doi:10.1002/(sici)1097-0142(19970501)79:9
Cerivastatin Improves Survival of Mice with Lipopolysaccharide-Induced Sepsis
Ando, H., Takamura, T., Ota, T., Nagai, Y., & Kobayashi, K. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39169-4 · Cited by 192
Interleukin-1 blockade in cardiovascular diseases: a clinical update
Buckley, L. F., & Abbate, A. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy128 · Cited by 202
Enteral nutrition with eicosapentaenoic acid, γ-linolenic acid, and antioxidants reduces alveolar inflammatory mediators and protein influx in patients with acute respiratory distress syndrome
Pacht, E. R., DeMichele, S. J., Nelson, J. L., Hart, J., Wennberg, A. K., & Gadek, J. E. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000049952.96496.3e · Cited by 191
“A variety of these agents include ibuprofen (48), prostaglandin E1 (49, 50), prostacyclin (51, 52), antiendotoxin antibodies (53), IL-1 receptor antagonists (54, 55), anti-TNF antibodies (56), intravenous N-acetylcysteine (57, 58), nitric oxide (59), and Ketoconazole, a thromboxane A2 synthetase inhibitor (60).”
Background
The Next Generation of Sepsis Clinical Trial Designs
Opal, S. M., Dellinger, R. P., Vincent, J., Masur, H., & Angus, D. C. (2014) · Critical Care Medicine · doi:10.1097/ccm.0000000000000325 · Cited by 191
Renal replacement therapy with high-cutoff hemofilters: impact of convection and diffusion on cytokine clearances and protein status
Morgera, S., Slowinski, T., Melzer, C., et al. (2004) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2003.11.006 · Cited by 190

Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist for Sepsis Varies by Initial Interleukin-1 Receptor Antagonist Plasma Concentration*
Meyer, N. J., Reilly, J. P., Anderson, B. J., Palakshappa, J. A., Jones, T. K., Dunn, T. G., Shashaty, M. G. S., Feng, R., Christie, J. D., & Opal, S. M. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002749 · Cited by 99
Studying the Pharmacokinetics of Interleukin-1RA Mutants
Khuzaima, I., Iftikhar, K., Tabarruk, U., et al. (2019) · BioScientific Review · doi:10.32350/bsr.0101.02 · Cited by 1
Activity of an Interleukin 1 Receptor Antagonist in Rabbit Models of Uveitis
Rosenbaum, J. T. (1992) · Archives of Ophthalmology · doi:10.1001/archopht.1992.01080160125049 · Cited by 58
Role of Interleukin-1/Interleukin-1 Receptor Antagonist Family of Cytokines in Long-Term Continuous Glucose Monitoring In Vivo
Klueh, U., Antar, O. S., Qiao, Y., & Kreutzer, D. L. (2013) · Journal of Diabetes Science and Technology · doi:10.1177/193229681300700614 · Cited by 10
Correlation between osteoarthritis and interleukin-1 receptor antagonist
Guang-yong, G. (2007) · Yixue yanjiusheng xuebao

Authors: Fisher, C. J.
Corresponding author: Fisher, Charles J.
ORCID: Fisher, Charles J.
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 1994-06-15
Volume: 271
Issue: 23
Pages: 1836
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.1994.03510470040032
OpenAlex: W4322697531
Cited by: 790
References: 0
Citations by year: 2026: 11 · 2025: 23 · 2024: 18 · 2023: 28 · 2022: 15 · 2021: 18 · 2020: 32 · 2019: 23 · 2018: 24 · 2017: 22 · 2016: 19 · 2015: 18 · 2014: 30 · 2013: 20 · 2012: 22
FWCI: 37.99
Type: journal article
Language: en
Open access: closed
Locations: JAMA (publishedVersion)
Topics: Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
Life Sciences › Immunology and Microbiology › Immunology › Inflammation biomarkers and pathways
Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
Keywords: sepsis, septic shock, survival, organ dysfunction, mortality risk, dose-response relationship, drug safety, cytokine inhibition

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks